Taken together, it presently appears that amongst individuals with HF, those most likely to benefit from GLP-1 RA treatment are people living with or at risk of developing obesity-related (with or without diabetes) HFpEF. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.